Liquid biopsy in diagnosis and monitoring of treatment efficacy in patients with small cell lung cancer DOI Creative Commons
Natalia Galant, Anna Grenda, Paweł Krawczyk

et al.

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: May 13, 2025

Small-cell lung cancer (SCLC) remains one of the deadliest cancers worldwide. Patients' survival poor due to its rapid growth, high metastatic rate and limited possibilities treatment. For many years, SCLC management has been based mostly on chemo radiotherapy. However, new therapeutic approaches have proposed in past few including immunotherapy, which is currently implemented clinical practice. Unfortunately, cases, response therapy, especially chemotherapy, poor, or patient becomes resistant initially effective One crucial problems during care a lack appropriate predictive biomarkers for various approaches. Another critical issue scarcity collected tissue biopsy, may be insufficient too quality analysis. A liquid biopsy might key solving both those as it non-invasive way enables measurement biomarkers, circulating tumor DNA (ctDNA) cells (CTCs). In this review, we discuss potentially incorporating into application - companion imaging diagnostics, approach molecular subtyping, material enabling prognostic assessment. We also summarize ongoing trials encompassing patients examined.

Language: Английский

Liquid biopsy in diagnosis and monitoring of treatment efficacy in patients with small cell lung cancer DOI Creative Commons
Natalia Galant, Anna Grenda, Paweł Krawczyk

et al.

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: May 13, 2025

Small-cell lung cancer (SCLC) remains one of the deadliest cancers worldwide. Patients' survival poor due to its rapid growth, high metastatic rate and limited possibilities treatment. For many years, SCLC management has been based mostly on chemo radiotherapy. However, new therapeutic approaches have proposed in past few including immunotherapy, which is currently implemented clinical practice. Unfortunately, cases, response therapy, especially chemotherapy, poor, or patient becomes resistant initially effective One crucial problems during care a lack appropriate predictive biomarkers for various approaches. Another critical issue scarcity collected tissue biopsy, may be insufficient too quality analysis. A liquid biopsy might key solving both those as it non-invasive way enables measurement biomarkers, circulating tumor DNA (ctDNA) cells (CTCs). In this review, we discuss potentially incorporating into application - companion imaging diagnostics, approach molecular subtyping, material enabling prognostic assessment. We also summarize ongoing trials encompassing patients examined.

Language: Английский

Citations

0